Everything below concerns analytical characterisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
===== MeSH D08.811.520.241 – carbon-oxygen lyases (EC 4.2) ===== MeSH D08.811.520.241.225 – DNA-(apurinic or apyrimidinic site) lyase MeSH D08.811.520.241.300 – hydro-lyases MeSH D08.811.520.241.300.050 – aconitate hydratase MeSH D08.811.520.241.300.050.500 – iron regulatory protein 1 MeSH D08.811.520.241.300.050.750 – iron regulatory protein 2 MeSH D08.811.520.241.300.150 – carbonic anhydrases MeSH D08.811.520.241.300.150.100 – carbonic anhydrase i MeSH D08.811.520.241.300.150.200 – carbonic anhydrase ii MeSH D08.811.520.241.300.150.300 – carbonic anhydrase iii MeSH D08.811.520.241.300.150.400 – carbonic anhydrase iv MeSH D08.811.520.241.300.150.500 – carbonic anhydrase v MeSH D08.811.520.241.300.200 – cystathionine beta-synthase MeSH D08.811.520.241.300.250 – enoyl-coa hydratase MeSH D08.811.520.241.300.300 – fumarate hydratase MeSH D08.811.520.241.300.500 – phosphopyruvate hydratase MeSH D08.811.520.241.300.500.500 – tau-crystallins MeSH D08.811.520.241.300.550 – porphobilinogen synthase MeSH D08.811.520.241.300.600 – prephenate dehydratase MeSH D08.811.520.241.300.650 – propanediol dehydratase MeSH D08.811.520.241.300.850 – tryptophan synthase MeSH D08.811.520.241.300.900 – urocanate hydratase MeSH D08.811.520.241.300.950 – uroporphyrinogen iii synthetase MeSH D08.811.520.241.700 – polysaccharide-lyases MeSH D08.811.520.241.700.350 – chondroitinases and chondroitin lyases MeSH D08.811.520.241.700.350.500 – chondroitin lyases MeSH D08.811.520.241.700.350.500.500 – chondroitin abc lyase MeSH D08.811.520.241.700.512 – heparin lyase MeSH D08.811.520.241.700.675 – hyaluronoglucosaminidase
Using the money from her portraits, Jolene leaves and boards a bus west out of South Carolina. Jolene resorts to hitchhiking further west, supporting herself by prostitution. Jolene ends up in Arizona, working as a waitress at an outdoor diner. There, she meets Coco Leger, an aspiring musician and tattoo artist. A relationship blossoms between them and Jolene becomes a tattoo artist at Coco's parlor. After two weeks of dating, Jolene moves in with Coco and he convinces her to get married. After he passes out during sex, Coco is revealed to have a cocaine addiction, supporting his habit and the parlor by dealing cocaine. One evening, a young woman enters the parlor and declares herself to be his wife, Marin and introduces their son, Coco Jr. Coco returns and is confronted by both women before he walks out with Marin and the baby. Furious with Coco, Jolene destroys the parlor, dumps the cocaine on a table, steals the drug money and dumps her ring in the center of the cocaine before dialing 911 and fleeing the scene. Jolene later is in Las Vegas, working as an erotic dancer when she meets Sal Fontaine, a mobster. He takes a liking to her and invites her to quit dancing and move into his high rise condo. Jolene enjoys a life of luxury with Sal, going to fancy dinners and exploring her talent as an artist. One night, Sal demands that Jolene get dressed, go downstairs and wait for him. She falls asleep in the restaurant and quietly returns to the condo to find Sal dead and the mob looking for her. Jolene escapes and ends up hitchhiking on a truck to Tulsa.
== Definition == The term secretome was coined by Tjalsma and colleagues in 2004 to denote all the factors secreted by a cell, along with the secretory pathway constituents. In 2010, this definition of secretome was revised to include only proteins secreted into the extracellular space. Related concepts include the matrisome, which is the subset of the secretome that includes extracellular matrix proteins and their associated proteins; the receptome, which includes all membrane receptors, and the adhesome, which includes all proteins involved in cell adhesion.
Sources: en.wikipedia.org
=== Energy === In July 2018, Minister Rickford tabled Bill 2: Urgent Priorities Act, which received Royal Assent in the same month. The first session of the 42nd Legislature was on July 11 and Bill 2, which passed into law on July 25, was the Ford Government's first piece of legislation. Bill 2—an omnibus bill—was "criticized by both "business groups and unions". It legislated an end to the strike between York University and Canadian Union of Public Employees (CUPE), cancelled the White Pines Wind Project wind farm contract, and gave Ontario government "veto power over compensation at Hydro One." In December 2025, Ford and New York governor Kathy Hochul signed a memorandum of understanding which makes the New York Power Authority and Ontario Power Generation work together on advancing nuclear energy technology. In July 2026, Ford and Alberta premier Danielle Smith proposed an oil pipeline from Alberta to Sarnia, Ontario.
== Method principle == Before the introduction of the first automated cell counters, hematologists were referred to manual cell count under the microscope. The Celloscope method for automated counting of blood cells was described in an article by Öhlin in 1958. In the described method, cells in a saline (conductive) solution are allowed to pass through a capillary with a length and diameter corresponding to the size of blood cells. At the same time, an electric current passes the capillary, and each cell then gives rise to an electric pulse through the increase in resistance that it causes in the electric circuit. The number of pulses is recorded and corresponds to the number of cells in a certain volume. Diluting the blood sample to a sufficient extent for the distance between the cells when passing through the capillary to be greater than the dimension of the cells and capillary ensures that each cell is counted individually. As cells are counted in an absolute volume of the suspension, the number of cells in mm3 of whole blood can be calculated using the dilution factor. The described automated Celloscope cell count method enabled an improved accuracy compared with manual examination by microscopy, while decreasing manual work for the operator. The method allows 50 000 cells to be counted in about 45 seconds, with high accuracy. The Celloscope counter was also equipped with a discriminator, or electrical threshold, which allows only pulses above a certain size to be counted, enabling different blood cells to be counted.
== History and chemistry == Diphenoxylate was first synthesized by Paul Janssen at Janssen Pharmaceutica in 1956 as part of a medicinal chemistry investigation of opioids. Diphenoxylate is made by combining a precursor of normethadone with norpethidine. Loperamide (Imodium) and bezitramide are analogs. Like loperamide, it has a methadone-like structure and a piperidine moiety.
Adoptive T cell therapy is a form of passive immunization by the transfusion of T-cells. They are found in blood and tissue and typically activate when they find foreign pathogens. Activation occurs when the T-cell's surface receptors encounter cells that display parts of foreign proteins (either on their surface or intracellularly). These can be either infected cells or other antigen-presenting cells (APCs). The latter are found in normal tissue and in tumor tissue, where they are known as tumor-infiltrating lymphocytes (TILs). They are activated by the presence of APCs such as dendritic cells that present tumor antigens. Although these cells can attack tumors, the tumor microenvironment is highly immunosuppressive, interfering with immune-mediated tumour death. Multiple ways of producing tumour-destroying T-cells have been developed. Most commonly, T-cells specific to a tumor antigen can be removed from a tumor sample (TILs) or filtered from blood. The T-cells can optionally be modified in various ways, cultured and infused into patients. T cells can be modified via genetic engineering, producing CAR-T cell or TCR T cells or by exposing the T cells to tumor antigens in a non-immunosuppressive environment, that they recognize as foreign and learn to attack. Another approach is transfer of haploidentical γδ T cells or natural killer cells from a healthy donor. The major advantage of this approach is that these cells do not cause graft-versus-host disease. The disadvantage is that transferred cells frequently have impaired function.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.